Strategies to achieve clinical effectiveness: Refining existing therapies and pursuing emerging targets

Journal of Affective Disorders

Volumn 132, Issue SUPPL. 1, 2011, Pages

  Kennedy, Sidney H ^a   Young, Allan H ^c   Blier, Pierre ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antidepressants; Effectiveness; Efficacy; Major depression; SSRI

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CYTOKINE; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FOLIC ACID; LIOTHYRONINE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE; NEUROPEPTIDE; NEUROTROPHIN; OMEGA 3 FATTY ACID; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; TRAZODONE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VENLAFAXINE;

CLINICAL EFFECTIVENESS; DEPRESSION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INDIVIDUALIZATION; LONG TERM CARE; MONOAMINERGIC SYSTEM; PATIENT SATISFACTION; PRIORITY JOURNAL; RELAPSE; RESEARCH; REVIEW; TOTAL QUALITY MANAGEMENT;

EID: 79960313397     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2011.03.048     Document Type: Article

References (96)

1. I.M. Anderson Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability J. Affect. Disord. 58 2000 19 36 (Pubitemid 30173208)
2. H. Anisman, Z. Merali, M.O. Poulter, and S. Hayley Cytokines as a precipitant of depressive illness: animal and human studies Curr. Pharm. Des. 11 2005 963 972 (Pubitemid 40331298)
3. A. Bachis, A. Mallei, and M.I. Cruz Chronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neurons Neuropharmacology 55 2008 1114 1120
4. R. Balon, and R.T. Segraves Survey of treatment practices for sexual dysfunction(s) associated with anti-depressants J. Sex Marital Ther. 34 4 2008 353 365 (Pubitemid 351896796)
5. V. Bartanusz, J.M. Aubry, and S. Pagliusi Stress-induced changes in messenger RNA levels of N-methyl-d-aspartate and AMPA receptor subunits in selected regions of the rat hippocampus and hypothalamus Neuroscience 66 1995 247 252
6. M. Bauer, P. Tharmanathan, H.P. Volz, H.J. Moeller, and N. Freemantle The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis Eur. Arch. Psychiatry Clin. Neurosci. 259 3 2009 172 185
7. J.K. Belanoff, A.J. Rothschild, and F. Cassidy An open label trial of C-1073 (mifepristone) for psychotic major depression Biol. Psychiatry 52 2002 386 392 (Pubitemid 35266729)
8. A. Bilkei-Gorzo, I. Racz, K. Michel, and A. Zimmer Diminished anxiety- and depression-related behaviors in mice with selective deletion of the Tac1 gene J. Neurosci. 22 2002 10046 10052 (Pubitemid 35332890)
9. C.M. Blasey, C. Debattista, R. Roe, T. Block, and J.K. Belanoff A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction Contemp. Clin. Trials 30 4 2009 284 288
10. P. Blier, G. Gobbi, J.E. Turcotte, C. de Montigny, N. Boucher, C. Hébert, and G. Debonnel Mirtazapine and paroxetine in major depression: comparison of monotherapy versus their combination Eur. Neuropsychopharmacol. 19 2009 457 465
11. P. Blier, H.E. Ward, P. Tremblay, L. Laberge, C. Hébert, and R. Bergeron Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study Am. J. Psychiatry 167 3 2010 281 288
12. A.R. Brunoni, R. Fraguas, and F. Fregni Pharmacological and combined interventions for the acute depressive episode: focus on efficacy and tolerability Ther. Clin. Risk Manag. 5 2009 897 910
13. L. Capuron, G. Neurauter, and D.L. Musselman Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment Biol. Psychiatry 54 2003 906 914 (Pubitemid 37311353)
14. A. Cipriani, T.A. Furukawa, and G. Salanti Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis Lancet 373 2009 746 758
15. R.K. Conley, M.J. Cumberbatch, and G.S. Mason Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity J. Neurosci. 22 2002 7730 7736 (Pubitemid 35390361)
16. T.J. Connor, and B.E. Leonard Depression, stress and immunological activation: the role of cytokines in depressive disorders Life Sci. 62 1998 583 606 (Pubitemid 28045567)
17. C. DeBattista, J. Belanoff, S. Glass, A. Khan, R.L. Horne, C. Blasey, L.L. Carpenter, and G. Alva Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression Biol. Psychiatry 60 2006 1343 1349 (Pubitemid 44838535)
18. G. Debonnel, E. Saint-André, C. Hébert, C. de Montigny, N. Lavoie, and P. Blier Differential physiological effects of a low and high doses of venlafaxine in major depression Int. J. Neuropsychopharmacol. 10 2007 51 61 (Pubitemid 46122752)
19. S.C. Dilsaver Pathophysiology of "cholinoceptor supersensitivity" in affective disorders Biol. Psychiatry 21 1986 813 829 (Pubitemid 16044005)
20. R.S. Duman, and L.M. Monteggia A neurotrophic model for stress-related mood disorders Biol. Psychiatry 59 2006 1116 1127
21. C.H. Duman, L. Schlesinger, and R. Terwilliger Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise Behav. Brain Res. 198 2009 366 371
22. A.M. Feyissa, A. Chandran, C.A. Stockmeier, and B. Karolewicz Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression Prog. Neuropsychopharmacol Biol. Psychiatry 33 2009 70 75
23. M.L. Furey, and W.C. Drevets Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial Arch. Gen. Psychiatry 63 10 2006 1121 1129 (Pubitemid 44498391)
24. J.R. Geddes, N. Freemantle, J. Mason, M.P. Eccles, and J. Boynton SSRIs versus other antidepressants for depressive disorder Cochrane Database Syst. Rev. 2 2000 CD001851
25. J.R. Geddes, S.M. Carney, C. Davies, T.A. Furukawa, D.J. Kupfer, E. Frank, and G.M. Goodwin Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review Lancet 361 9358 2003 653 661 (Pubitemid 36246547)
26. T.P. George, K.A. Sacco, J.C. Vessicchio, A.H. Weinberger, and R.D. Shytle Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study J. Clin. Psychopharmacol. 28 3 2008 340 344
27. A. Germain, and D.J. Kupfer Circadian rhythm disturbances in depression Hum. Psychopharmacol. 23 2008 571 585
28. B.P. Guiard, M. El Mansari, Z. Merali, and P. Blier Functional interactions between dopamine, serotonin and norepinephrine neurons: an in vivo electrophysiological study in rats with monoaminergic lesions Int. J. Neuropsychopharmacol. 11 2008 625 639 (Pubitemid 351931823)
29. B.P. Guiard, F. Chenu, M.E. Mansari, and P. Blier Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons Int. J. Neuropsychopharmacol. 2010 1 13
30. D.A. Gutman, M.J. Owens, and C.B. Nemeroff CRF receptor and glucocorticoid receptor antagonists: new approaches to antidepressant treatment J.A. den Boer, M.S. George, G.T. ter Horst, Current and Future Developments in Psychopharmacology 2005 Benecke, NI Amsterdam 133 158
31. R. Hargreaves Imaging substance P receptors (NK1) in the living human brain using positron emission tomography J. Clin. Psychiatry 263 Suppl 11 2002 18 24 (Pubitemid 35435004)
32. S.A. Heldt, L. Stanek, J.P. Chhatwal, and K.J. Ressler Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories Mol. Psychiatry 12 2007 656 670 (Pubitemid 46998249)
33. M.E. Hernández, D. Mendieta, and D. Martínez-Fong Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder Eur. Neuropsychopharmacol. 18 2008 917 924
34. F. Holsboer, and M. Ising Central CRH system in depression and anxiety-evidence from clinical studies with CRH1 receptor antagonists Eur. J. Pharmacol. 583 2008 350 357
35. J. Iga, S. Ueno, and K. Yamauchi Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder Prog Neuropsychopharmacol Biol. Psychiatry 31 2007 658 663 (Pubitemid 46476822)
36. D.S. Janowsky, D.H. Overstreet, and J.I. Nurnberger Jr. Is cholinergic sensitivity a genetic marker for the affective disorders? Am. J. Med. Genet. 54 1994 335 344
37. S. Kasper, G. Hajak, K. Wulff, W.J. Hoogendijk, A.L. Montejo, and E. Smeraldi Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline J. Clin. Psychiatry 71 2 2010 109 120
38. K. Kawai, A. Saito, T. Sudo, and H. Osada Specific regulation of cytokine-dependent p38 MAP kinase activation by p62/SQSTM1 J. Biochem. 143 2008 765 772 (Pubitemid 351918937)
39. S.H. Kennedy, and S.J. Rizvi Emerging drugs for major depressive disorder Expert Opin. Emerg. Drugs 14 3 2009 439 453
40. S.H. Kennedy, and S.J. Rizvi Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness CNS Drugs 24 6 2010 479 499
41. S.H. Kennedy, S. Rizvi, K. Fulton, and J. Rasmussen A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR J. Clin. Psychopharmacol. 28 3 2008 329 333
42. S.H. Kennedy, H.F. Andersen, and M.E. Thase Escitalopram in the treatment of major depressive disorder: a meta-analysis Curr. Med. Res. Opin. 25 2009 161 175
43. S.H. Kennedy, R.W. Lam, S.V. Parikh, S.B. Patten, and A.V. Ravindran Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. J. Affect. Disord. 117 Suppl 1 2009 S1 S2
44. S.G. Kornstein, D. Li, Y. Mao, S. Larsson, H.F. Andersen, and G.I. Papakostas Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials CNS Spectr. 14 6 2009 326 333
45. G. Laje, R.H. Perlis, A.J. Rush, and F.J. McMahon Pharmacogenetics studies in STAR*D: strengths, limitations, and results Psychiatr. Serv. 60 11 2009 1446 1457
46. R.W. Lam, S.H. Kennedy, and S. Grigoriadis Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy J. Affect. Disord. 117 Suppl 1 2009 S26 S43
47. C. Legros, S. Chalivoix, and C. Gabriel First evidence of melatonin receptors distribution in the suprachiasmatic nucleus of tree shrew brain Neuro Endocrinol. Lett. 28 2007 267 273 (Pubitemid 47045770)
48. M. Lekman, G. Laje, D. Charney, A.J. Rush, A.F. Wilson, and A.J. Sorant The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort Biol. Psychiatry 63 2008 1103 1110
49. P. Lemoine, C. Guilleminault, and E. Alvarez Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine J. Clin. Psychiatry 68 11 2007 1723 1732 (Pubitemid 350247502)
50. K.W. Lobello, S.H. Preskorn, C.J. Guico-Pabia, Q. Jiang, J. Paul, A.I. Nichols, A. Patroneva, and P.T. Ninan Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder J. Clin. Psychiatry 71 11 2010 1482 1487
51. H. Lôo, A. Hale, and H. D'haenen Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study Int. Clin. Psychopharmacol. 17 5 2002 239 247
52. R. Machado-Vieira, P. Yuan, N. Brutsche, N. DiazGranados, D. Luckenbaugh, H.K. Manji, and C.A. Zarate Jr. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-d-aspartate antagonist Clin. Psychiatry 70 2009 1662 1666
53. P.W. Mantyh Neurobiology of substance P and the NK1 receptor J. Clin. Psychiatry 63 suppl 1 2002 6 10
54. K.A. Maubach, K. Martin, and G. Chicchi Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus Neuroscience 109 2002 609 617 (Pubitemid 34122009)
55. J.L. Mayer, L. Klumpers, S. Maslam, E.R. de Kloet, M. Joëls, and P.J. Lucassen Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone-induced reduction of adult hippocampal neurogenesis J. Neuroendocrinol. 18 2006 629 631
56. F.J. McMahon, S. Buervenich, D. Charney, R. Lipsky, A.J. Rush, and A.F. Wilson Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment Am. J. Hum. Genet. 78 2006 804 814
57. A.H. Miller, V. Maletic, and C.L. Raison Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression Biol. Psychiatry 65 9 2009 732 741
58. R. Mojtabai, and M. Olfson National trends in psychotropic medication polypharmacy in office-based psychiatry Arch. Gen. Psychiatry 67 1 2010 26 36
59. N. Müller, M.J. Schwarz, S. Dehning, A. Douhe, A. Cerovecki, B. Goldstein-Müller, I. Spellmann, G. Hetzel, K. Maino, N. Kleindienst, H.J. Möller, V. Arolt, and M. Riedel The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine Mol. Psychiatry 11 7 2006 680 684 (Pubitemid 43989814)
60. C.J. Mussap, D.P. Geraghty, and E. Burcher Tachykinin receptors: a radioligand binding perspective J. Neurochem. 60 1993 1987 2008
61. H.A. Nasrallah, S.D. Targum, R. Tandon, J.S. McCombs, and R. Ross Defining and measuring clinical effectiveness in the treatment of schizophrenia Psychiatr. Serv. 56 3 2005 273 282 (Pubitemid 40333559)
62. C.B. Nemeroff, R. Entsuah, and I. Benattia Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs Biol. Psychiatry 63 2008 424 434
63. D.J. Nutt Relationship of neurotransmitters to the symptoms of major depressive disorder J. Clin. Psychiatry 69 Suppl E1 2008 4 7
64. S.M. O'Brien, P. Scully, P. Fitzgerald, L.V. Scott, and T.G. Dinan Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy J. Psychiatr. Res. 41 2007 326 331 (Pubitemid 44854992)
65. G.I. Papakostas, and M. Fava A meta analysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder Can. J. Psychiatry 51 2006 783 790 (Pubitemid 44656509)
66. G.I. Papakostas, C.H. Homberger, and M. Fava A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder J. Psychopharmacol. 22 8 2008 843 848
67. S.W. Park, Y.P. Yan, and I. Satriotomo Substance P is a promoter of adult neural progenitor cell proliferation under normal and ischemic conditions J. Neurosurg. 107 2007 593 599 (Pubitemid 47451044)
68. S.B. Patten, S.H. Kennedy, and R.W. Lam Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management J. Affect. Disord. 117 Suppl 1 2009 S5 S14
69. I.A. Paul, G. Nowak, and R.T. Layer Adaptation of the N-methyl-d-aspartate receptor complex following chronic antidepressant treatments J. Pharmacol. Exp. Ther. 269 1994 95 102 (Pubitemid 24143240)
70. S.H. Preskorn Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future J. Psychopharmacol. 20 2006 85 94 (Pubitemid 44576664)
71. S.H. Preskorn, B. Baker, S. Kolluri, F.S. Menniti, M. Krams, and J.W. Landen An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder J. Clin. Psychopharmacol. 28 6 2008 631 637
72. S. Preskorn, A. Patroneva, H. Silman, Q. Jiang, J.A. Isler, M.E. Burczynski, S. Ahmed, J. Paul, and A.I. Nichols Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers J. Clin. Psychopharmacol. 29 1 2009 39 43
73. T. Rantamäki, P. Hendolin, and A. Kankaanpää Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain Neuropsychopharmacology 32 2007 2152 2162 (Pubitemid 47417694)
74. I.J. Russell, P.J. Mease, and T.R. Smith Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial Pain 136 2008 432 444
75. M. Sairanen, G. Lucas, and P. Ernfors Brainderived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus J. Neurosci. 25 2005 1089 1094 (Pubitemid 40268949)
76. G. Salvadore, B.R. Cornwell, V. Colon-Rosario, R. Coppola, C. Grillon, C.A. Zarate Jr., and H.K. Manji Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine Biol. Psychiatry 65 4 2009 289 295
77. G. Sanacora, S.F. Kendell, and L. Fenton Riluzole augmentation for treatment-resistant depression Am. J. Psychiatry 161 2004 2132
78. R.M. Sapolsky The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death Biol. Psychiatry 48 2000 755 765
79. H.D. Schmidt, and R.S. Duman Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models 2010 Neuropsychopharmacology Epub Aug 4
80. A. Schosser, and S. Kasper The role of pharmacogenetics in the treatment of depression and anxiety disorders Int. Clin. Psychopharmacol. 24 6 2009 277 288
81. M.C. Serna, I. Cruz, J. Real, E. Gascó, and L. Galván Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database Eur. Psychiatr. 25 4 2010 206 213
82. Y. Shirayama, H. Mitsushio, and M. Takashima Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat Brain Res. 739 1996 70 78 (Pubitemid 26387364)
83. R.D. Shytle, A.A. Silver, and R.J. Lukas Nicotinic acetylcholine receptors as targets for antidepressants Mol. Psychiatry 7 2002 525 535
84. E. Souetre, E. Salvati, and J.L. Belugou Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality Psychiatr. Res. 28 1989 263 278 (Pubitemid 19165767)
85. V. Srinivasan, S.R. Pandi-Perumal, and I. Trakht Pathophysiology of depression: role of sleep and the melatonergic system Psychiatry Res. 165 2009 201 214
86. M. Thakur, I. Grossman, D.C. McCrory, L.A. Orlando, D.C. Steffens, K.E. Cline, R.N. Gray, J. Farmer, G. DeJesus, C. O'Brien, G. Samsa, D.B. Goldstein, and D.B. Matchar Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors Genet. Med. 9 2007 826 835 (Pubitemid 350295210)
87. M.E. Thase, A.R. Entsuah, and R.L. Rudolph Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors Br. J. Psychiatry 178 2001 234 241 (Pubitemid 32183606)
88. V. Trajkovska, L. Kirkegaard, G. Krey, A.B. Marcussen, M.S. Thomsen, S. Chourbaji, C. Brandwein, S. Ridder, C. Halldin, P. Gass, G.M. Knudsen, and S. Aznar Activation of glucocorticoid receptors increases 5-HT2A receptor levels Exp. Neurol. 218 1 2009 83 91
89. M.H. Trivedi, A.J. Rush, S.R. Wisniewski, A.A. Nierenberg, D. Warden, L. Ritz, G. Norquist, R.H. Howland, B. Lebowitz, P.J. McGrath, K. Shores-Wilson, M.M. Biggs, G.K. Balasubramani, M. Fava STAR*D Study Team Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice Am. J. Psychiatry 163 2006 28 40 (Pubitemid 43050100)
90. M.H. Trivedi, E. Hollander, D. Nutt, and P. Blier Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression J. Clin. Psychiatry 69 2 2008 246 258 (Pubitemid 351469268)
91. D. Warden, A.J. Rush, M.H. Trivedi, M. Fava, and S.R. Wisniewski The STAR*D project results: a comprehensive review of findings Curr. Psychiatry Rep. 9 6 2007 449 459 (Pubitemid 350284935)
92. M.H. Wiegand Antidepressants for the treatment of insomnia: a suitable approach? Drugs 68 17 2008 2411 2417
93. A.H. Young, P. Gallagher, and S. Watson Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder Neuropsychopharmacology 29 2004 1538 1545 (Pubitemid 38982247)
94. C.A. Zarate Jr., J. Du, and J. Quiroz Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system Ann. N.Y. Acad. Sci. 1003 2004 273 291
95. C.A. Zarate Jr., J.B. Singh, and P.J. Carlson A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression Arch. Gen. Psychiatry 63 8 2006 856 864 (Pubitemid 44188478)
96. C.A. Zarate Jr., J.B. Singh, and P.J. Carlson A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression Arch. Gen. Psychiatry 63 8 2006 856 864 (Pubitemid 44188478)